On Friday, Immunic Inc (IMUX) stock saw a decline, ending the day at $1.19 which represents a decrease of $-0.02 or -1.65% from the prior close of $1.21. The stock opened at $1.21 and touched a low of ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis 22.10.2024 / 12:30 CET/CEST The issuer is solely responsible ...

On Thursday, Immunic Inc (IMUX) stock saw a modest uptick, ending the day at $1.59 which represents a slight increase of $0.05 or 3.25% from the prior close of $1.54. The stock opened at $1.54 and ...

A pair of Phase 3 trials testing vidofludimus calcium in relapsing MS are continuing as planned after a positive committee ...

Arizona Gold and Silver Inc. continues the hunt for large, high-grade targets at its projects in the US state ...

NEW YORK, Oct. 22, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...

Immunic to Participate in Industry, Scientific and Investor Conferences in November 29.10.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to ...

NEW YORK, October 29, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

NEW YORK, October 29, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Members of Immunic's management, business development and investor relations teams will participate in partnering activities at this conference in Stockholm, Sweden. To schedule a meeting ...